Tessa Rademaker‐Havinga

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Pascal Vranckx, Marco Valgimigli, Peter Jüni et al. · The Lancet · 2018 · 785 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16

Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease

Patrick W. Serruys, Vasim Farooq, Bindu Kalesan et al. · JACC: Cardiovascular Interventions · 2013 · 331 citations

Medicine, Biomedical Engineering, Cardiology +14

2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice

Pieter C. Smits, Elvin Kedhi, Kees‐Jan Royaards et al. · Journal of the American College of Cardiology · 2011 · 193 citations

Medicine, Cardiology, Surgery +17

Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes

Mariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma et al. · JAMA Cardiology · 2019 · 134 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial

William Wijns, Philippe Gabríel Steg, Laura Mauri et al. · European Heart Journal · 2014 · 66 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17